Abnormalities of liver sinusoidal endothelial cells in primary biliary cholangitis

Figure 1 Primary biliary cholangitis before (30 patients) and after ursodeoxycholic acid treatment (25 patients) compared to 12 normal controls and 15 patients with chronic hepatitis C virus. Values for early (18 patients) and late primary biliary cholangitis (12 patients) are also presented. A: Soluble vascular cell adhesion molecule levels; B: Soluble intercellular adhesion molecule levels; C: Soluble E selectin levels; D: Serum tissue plasminogen activator; E: Serum plasminogen activator inhibitor-1. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. NS: Not significant; sVCAM: Soluble vascular cell adhesion molecule; HCV: Hepatitis C virus; PBCb: Primary biliary cholangitis before treatment with ursodeoxycholic acid; PBCa: Primary biliary cholangitis after treatment with ursodeoxycholic acid; PBC: Primary biliary cholangitis; sICAM: Soluble intercellular adhesion molecule levels; eSelectin: Soluble E-selectin; t-PA: Tissue plasminogen activator; PAI: Plasminogen activator inhibitor 1.

Figure 2 Time points expression in EA. hy926 cells after incubation with serum from primary biliary cholangitis and chronic hepatitis C virus patients compared to controls considered as 1.0. Each bar represents the mean ± SD of 5 experiments. A: Endothelin 1 expression; B: Endothelin 2 expression; C: Endothelin 3 expression; D: Endothelin receptor A expression; E: Endothelin receptor B expression. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. NS: Not significant; ET: Endothelin; PBC: Primary biliary cholangitis; HCV: Hepatitis C virus; ENDRA: Endothelin receptor A; ENDRB: Endothelin receptor B.